Black Diamond Therapeutics (BDTX) Non-Current Assets (2018 - 2026)
Black Diamond Therapeutics' (BDTX) quarterly Non-Current Assets came in at $10.0 million in Q1 2026, down 51.59% YoY from $20.6 million in Q1 2025, and down 5.82% on a QoQ basis from $10.6 million in Q4 2025.
Black Diamond Therapeutics (BDTX) Non-Current Assets (2018 - 2026) Analysis & Trends
Black Diamond Therapeutics (BDTX) has 9 years of Non-Current Assets data on file, last reported at $10.0 million in Q1 2026.
- Quarterly Non-Current Assets fell 51.59% year-over-year to $10.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $58.9 million (down 32.75% YoY) and the FY2025 annual result came in at $10.6 million, down 50.75% from the prior year.
- Non-Current Assets fell to $10.0 million in Q1 2026, from $10.6 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $31.2 million in Q1 2022 to a low of $10.0 million in Q1 2026.
- A 5-year average of $23.2 million and a median of $23.7 million in 2024 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets soared 95.94% — and 2026, when it sank 51.59%.
- Tracing BDTX's Non-Current Assets over 5 years: stood at $28.5 million in 2022, then declined by 14.07% to $24.5 million in 2023, then fell by 12.51% to $21.5 million in 2024, then plunged by 50.75% to $10.6 million in 2025, then slipped by 5.82% to $10.0 million in 2026.
- The last three Non-Current Assets figures came in at $10.0 million (Q1 2026), $10.6 million (Q4 2025), and $18.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Black Diamond Therapeutics | 125.92 Mn | 15.42 Mn | - | 9.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.64 Mn |
| Mar 31, 2026 | 9.96 Mn |
| Dec 31, 2025 | 10.57 Mn |
| Sep 30, 2025 | 18.74 Mn |
| Jun 30, 2025 | 19.66 Mn |
| Mar 31, 2025 | 20.57 Mn |
| Dec 31, 2024 | 21.46 Mn |
| Sep 30, 2024 | 22.36 Mn |
| Jun 30, 2024 | 23.23 Mn |
| Mar 31, 2024 | 23.72 Mn |
| Dec 31, 2023 | 24.53 Mn |
| Sep 30, 2023 | 25.33 Mn |
| Jun 30, 2023 | 26.89 Mn |
| Mar 31, 2023 | 27.61 Mn |
| Dec 31, 2022 | 28.55 Mn |
| Sep 30, 2022 | 29.44 Mn |
| Jun 30, 2022 | 30.28 Mn |
| Mar 31, 2022 | 31.18 Mn |
| Dec 31, 2021 | 31.98 Mn |
| Sep 30, 2021 | 32.58 Mn |